Immunotherapy has become a viable treatment modality for a variety of cancers (and referred to as Science Magazine’s “Breakthrough of the Year” in 2013, as well as ASCO’s “Advance of the Year” in both 2016 and 2017). This Special Issue is focused on the relevance of immunobiology in brain tumors, touching on elements of immune suppression, immune stimulation, and the immune microenvironment, with culminations in translational immunotherapy
Immunotherapy is now advancing at remarkable pace for tumors located in various tissues, including t...
Glioma is one of the most devastating cancers, affecting children and young adults, and associated w...
For the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor ...
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue...
The development of immunotherapies has revolutionized intervention strategies for a variety of prima...
Central nervous system (CNS) tumors, although rare, represent a group of neoplasms that have a dispr...
The brain is one of the most complex organs of the human body. For a long time, it was thought that ...
Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor. Despi...
Glioblastoma (GBM), a WHO grade IV brain tumor, is an aggressive tumor with poor prognosis; even wit...
Harnessing the effector mechanisms of the immune system to combat brain tumors with antigen specific...
Glioblastomas are highly aggressive tumors. Their prognosis remain poor despite standard therapies c...
Human primary brain cancer is one of the most lethal and clinically challenging malignancies. The fa...
Immunotherapy has been demonstrably effective against various cancers, particularly those in the hem...
Until very few years ago, the oncology community dogmatically excluded any clinical potential for im...
Despite significant advances in our understanding of the pathobiology of brain tumors and their trea...
Immunotherapy is now advancing at remarkable pace for tumors located in various tissues, including t...
Glioma is one of the most devastating cancers, affecting children and young adults, and associated w...
For the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor ...
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue...
The development of immunotherapies has revolutionized intervention strategies for a variety of prima...
Central nervous system (CNS) tumors, although rare, represent a group of neoplasms that have a dispr...
The brain is one of the most complex organs of the human body. For a long time, it was thought that ...
Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor. Despi...
Glioblastoma (GBM), a WHO grade IV brain tumor, is an aggressive tumor with poor prognosis; even wit...
Harnessing the effector mechanisms of the immune system to combat brain tumors with antigen specific...
Glioblastomas are highly aggressive tumors. Their prognosis remain poor despite standard therapies c...
Human primary brain cancer is one of the most lethal and clinically challenging malignancies. The fa...
Immunotherapy has been demonstrably effective against various cancers, particularly those in the hem...
Until very few years ago, the oncology community dogmatically excluded any clinical potential for im...
Despite significant advances in our understanding of the pathobiology of brain tumors and their trea...
Immunotherapy is now advancing at remarkable pace for tumors located in various tissues, including t...
Glioma is one of the most devastating cancers, affecting children and young adults, and associated w...
For the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor ...
DOI
Add to ORKG